Abstract
Combination therapy with the PD-1 inhibitor pembro and the VEGF inhibitor lenvatinib showed activity in patients (pts) with advanced ccRCC in the phase III KEYNOTE-581/CLEAR trial. The HIF-2α inhibitor belzutifan (MK-6482) and MK-1308A, a coformulation of pembro and the CTLA-4 inhibitor quavonlimab, have each shown antitumor activity in phase I/II trials. HIF-2α or CTLA-4 inhibition with PD-1 and VEGF inhibition backbone combination may provide additional benefit as 1L treatment in ccRCC.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
